Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                    
 
Home      About      Team      Clients      Publications      Downloads      News      Contact            

Testimonials
  Bioscience Valuation's unique approach to portfolio management clearly enhanced the value of our R&D pipeline.

Prof. Dr. Klaus Nickisch, CSO Evestra Inc., formerly Head of Project Management at Bayer Schering Pharma AG

 

Core Services
  Financial Valuation
  Commercial Assessment &
Pharmacoeconomics

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

Products
  Market Model
  R&D Risk Model
  Valuation Model

About Bioscience Valuation

Bioscience Valuation was founded in the year 2000. At that time it became increasingly important to demonstrate value propositions to inform rational investment decisions by owners and investors, taking advantage of all available information and using advanced R&D, commercial and financial modeling. Bioscience Valuation provides these services to many successful clients.

Today, pharmaceutical companies face equally challenging times characterized by decreasing R&D productivity and higher hurdles to gain market access. The future will be shaped by advancing personalized treatments, taking companion-diagnostic, genomic and proteomic information into account. This creates economic challenges on its own.

"We combine in-depth commercial, R&D, economic and financial expertise with analytic capabilities that are second to none, and we use our strengths to enable senior management to achieve its goals. We do so by generating validated, fact-based evidence that forms the basis for persuasive arguments and convincing communications."

Joachim M. Greuel, Ph.D., MBA, Co-Founder and Managing Director

Bioscience Valuation is a member of

  • the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), USA,
  • the Personalized Medicine Coalition (PMC), USA,
  • the American Finance Association, USA.